FOLD News and Press, Amicus Therapeutics Inc. From 09/05/22

Summary This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. From 1/2/2016 to date investing in all 50 stocks, equally weighted, would have produced a total retu...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...

Amicus Therapeutics' AT-GAA approval in Pompe Disease has been pushed back by 3 months. However, the stock seems buoyant enough. I will continue holding, taking profits where I can. In my previous coverage in May, I wrote the following desultory text: Amicus Th...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q1-2022 13F filings the consensus holdings were updated, 10 stocks were removed and 8 added from the univ...

Amicus Therapeutics, Inc. (FOLD) Q2 2022 Earnings Conference Call August 04, 2022, 08:30 ET Company Participants Andrew Faughnan - Senior Director, IR Bradley Campbell - CEO, President & Director Sebastien Martel - Chief Business Officer Jeffrey Castelli ...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Amicus Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation

Amicus Therapeutics press release ( NASDAQ: FOLD ): Q2 GAAP EPS of -$0.21 beats by $0.01 . Revenue of $80.7M (+4.3% Y/Y) misses by $5.18M . For the full-year 2022, the company anticipates total Galafold revenue of $350 million to $365 million at constant exchan...

1H22 Galafold ® Revenue of $159.4M, reflecting 11% Sales Growth with Operational Growth of 18%, Partly Offset by Currency Headwinds of 7% On-Track to Deliver Full-Year Double-Digit Revenue Growth of 15-20% at Constant Exchange Rat...

Amicus Therapeutics ( NASDAQ: FOLD ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.22 (-15.8% Y/Y) and the consensus Revenue Estimate is $85.88M (+11.0% Y/Y). Over the last 1 year, FOLD has...

PHILADELPHIA, July 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2022 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2022. I...